Dr. Roger Lu Sur, MD

Dr. Sur practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Sur's NPI, 1932208022, was assigned on September 22, 2006. Dr. Sur graduated from Macon & Joan Brock Virginia Health Sciences Eastern Virginia Medical School in 1993. Dr. Sur holds California license G80585.

Dr. Sur's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Sur's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Sur is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sur practices. Vendor and product names are available with a free account.

Urology is Dr. Sur's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Sur is board certified in urology by the American Board of Urology. Dmand AI has Dr. Sur's licenses on file in 2 states: California and North Carolina.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney removal surgery, kidney stone disease, kidney stones, urinary endoscopy and urine flow blockage among the conditions Dr. Sur treats.

CMS data shows 267 Medicare services from Dr. Sur across 11 procedure codes in 2024, for 179 Medicare patients. Medicare paid $34,525 for them.

CMS counts 179 Medicare patients who saw Dr. Sur in 2024. The largest group is 65 to 74, with 93 patients. 74% of them have high cholesterol, and 73% have high blood pressure. 27% are also on Medicaid. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sur's median patient age at 65, with 38% women.

In 2024, Dr. Sur wrote 326 Medicare Part D claims for 118 patients. 92% of them were for generic drugs. CMS names the drug for 221 of them, across 7 drugs with 11 or more claims each, at $25,333 in total drug cost. In 2023, CMS named 370 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Sur for performance year 2024, reported as part of a group. Dr. Sur accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sur as offering telehealth. CMS counts 20 procedures of prostate resection by Dr. Sur, more than 81% of the clinicians it reports for that procedure.

Dmand AI links 96 papers to Dr. Sur, published from 2007 to 2024. 2020 was the busiest year, with 8. The most frequent topics are Kidney Calculi, Nephrolithotomy, Percutaneous and Ureteroscopy. Dr. Sur has published most often in J Endourol. Dr. Sur's most frequent co-authors are Seth K. Bechis, MD, Jonathan Henry Berger, MD and Vincent Gerard Bird, MD.

Dmand AI links Dr. Sur to 5 clinical trials, 2 of them phase 4 studies. 1 is still active or recruiting. Conditions studied include Urolithiasis, Kidney Calculi and Nephrolithiasis. University of California, San Diego sponsors the most, 3.

CMS Open Payments shows 625 general payments to Dr. Sur from 35 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 52% of the total. Boston Scientific Corporation paid the most, $523,876.

Dmand AI lists 2 awards for Dr. Sur, most recently San Diego Magazine Top Doctor in 2018. Dr. Sur serves on Perioperative OPP Block time subcommittee and Robotic committee.

Dr. Sur graduated from Macon & Joan Brock Virginia Health Sciences Eastern Virginia Medical School in 1993. Dr. Sur is a member of AUA and CMA.

Dr. Sur is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.